证券代码：300841 证券简称：康华生物 公告编号：2026-009 成都康华生物制品股份有限公司 关于ACYW135群脑膜炎球菌结合疫苗 获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，成都康华生物制品股份有限公司（以下简称"公司"）研发的ACYW135 群脑膜炎球菌结合疫苗获得国家药品监督管理局签发的《药物临床试验批准通知 书》，同意开展该疫苗的临床试验。现将相关情况公告如下： 主要审批结论：根据《中华人民共和国药品管理法》、《中华人民共和国疫 苗管理法》及有关规定，经审查，2025年12月12日受理的ACYW135群脑膜炎球 菌结合疫苗符合药品注册的有关要求，同意开展预防A群、C群、Y群和W135群 脑膜炎球菌引起的流行性脑脊髓膜炎的临床试验。 四、风险提示 疫苗产品具有研发周期长、技术难度大、研发风险高等特点，同时考虑到外 部环境因素的变化，疫苗产品研发成果能否顺利实现规模化生产、销售存在一定 不确定性因素，公司将根据研发进展情况及时履行信息披露义务，敬请广大投资 者谨慎决策，注意防范投资风险。 特此公告。 成都康 ...

Group 1 - The company, Kanghua Biological (300841), responded to investor inquiries on its operational status, indicating that stakeholders should refer to the company's regular reports for updates [1]

证券代码：300841 证券简称：康华生物 公告编号：2026-008 成都康华生物制品股份有限公司 关于审计机构变更质量控制复核人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 肖菲先生近三年未受到任何刑事处罚，未因执业行为受到证监会及其派出机 构、行业主管部门等的行政处罚或监督管理措施，未因执业行为受到证券交易所、 行业协会等自律组织的自律监管措施、纪律处分，不存在违反《中国注册会计师 职业道德守则》对独立性要求的情形。 三、其他说明 本次变更质量控制复核人系审计机构内部工作调整，本次变更过程中相关工 作安排已有序交接，变更事项不会对公司 2025 年度财务报表审计和 2025 年末财 务报告内部控制审计工作产生不利影响。 四、备查文件 成都康华生物制品股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第三届董事会第六次会议和第三届监事会第六次会议，审议通过了《关于 续聘公司 2025 年度审计机构的议案》，同意公司续聘立信会计师事务所（特殊 普通合伙）（以下简称"立信"）为公司 2025 年度审计机构，具体内容详见公 司于 2 ...

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. announced a strategic decision to acquire 100% control of Nameixin Biotech through a phased capital increase and equity transfer, marking a significant integration of innovative biotech with a mature industrial platform [1][11]. Part 01: Nameixin Biotech - Nameixin, established in 2021, focuses on mRNA vaccine and drug development, emphasizing AI-driven innovation and addressing unmet clinical needs [12][13]. - The founding team has over 20 years of experience in virology, immunology, and vaccine development, with key members having held significant positions in top research institutions and multinational corporations [2][13]. - Nameixin has developed a comprehensive technology platform covering target screening, antigen design, mRNA sequence optimization, LNP delivery system development, and lyophilized formulation processes [13][15]. - The company has applied for 14 invention patents, including one PCT international patent, and has obtained six software copyright registrations [15]. - Nameixin's core product, the RSV mRNA vaccine NR222, received clinical trial approval in December 2024, becoming the first lyophilized mRNA vaccine to enter clinical trials in China [6][17]. Part 02: Kanghua Biological - Founded in 2004, Kanghua is the first company in China to produce and sell human diploid cell rabies vaccines, recognized as a "gold standard" by WHO [7][18]. - The company is transitioning from a single product focus to a multi-product strategy, planning to expand into mRNA, recombinant protein/VLP, polysaccharide protein conjugates, and novel adjuvants [18]. - Kanghua's acquisition by Shanghai Biomedical Investment Fund marks a new development phase, with a 21.91% stake acquired [18][20]. - The company has established a strong academic promotion system covering thousands of disease control centers across China, enhancing its brand influence [19]. Part 03: Collaborative mRNA Vaccine Development - The collaboration between Nameixin and Kanghua aims to create a closed loop in mRNA vaccine development, production, and market access [19]. - Kanghua's existing production and R&D facilities, including a 14,000 square meter lab in Wenjiang, provide a solid foundation for large-scale GMP production and quality management [19]. - The partnership will leverage Shanghai's strategic position to enhance collaboration with universities, research institutions, and clinical organizations, facilitating international research pathways [20][21]. - The integration of Nameixin's innovative technology with Kanghua's industrial capabilities is expected to address long-standing clinical needs and enhance the accessibility of mRNA vaccines [21].

Market Overview - The biopharmaceutical sector increased by 0.65% on February 4, with Weiguang Bio leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Individual Stock Performance - Weiguang Bio (002880) closed at 30.72, up 7.79% with a trading volume of 106,600 shares and a transaction value of 320 million yuan [1] - Kanglaweishi (920575) closed at 11.07, up 5.63% with a trading volume of 105,200 shares and a transaction value of 114 million yuan [1] - Kangchen Pharmaceutical (603590) closed at 41.61, up 5.61% with a trading volume of 50,700 shares and a transaction value of 208 million yuan [1] - Other notable performers include Zhifei Biological (300122) up 2.61%, Kanghong Pharmaceutical (002773) up 2.31%, and Watson Bio (300142) up 1.92% [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 159 million yuan from institutional investors, while retail investors saw a net inflow of 187 million yuan [2] - The overall retail investor net outflow was 28.35 million yuan [2] Detailed Capital Flow for Selected Stocks - Wanze Co. (000534) had a net inflow of 67.22 million yuan from institutional investors, while retail investors experienced a net outflow of 99.26 million yuan [3] - Kangtai Biological (300601) saw a net inflow of 15.17 million yuan from institutional investors, with retail investors also experiencing a net outflow [3] - Shanghai Laisai (002252) had a net inflow of 14.01 million yuan from institutional investors, while retail investors faced a net outflow [3]

Core Viewpoint - The company plans to acquire 100% of Nameixin (Shanghai) Biotechnology Co., Ltd. through a three-phase investment strategy, with a total consideration of approximately 630 million yuan, marking a strategic shift towards mRNA vaccine innovation [1] Group 1: Acquisition Details - The acquisition will be executed in three phases, with the first phase involving a cash investment of 120 million yuan to secure approximately 27.27% equity and governance control [3] - The deal is structured with strict milestone conditions tied to the clinical progress of the RSV mRNA vaccine and HPV therapeutic vaccine, effectively managing short-term risks while enabling long-term collaborative growth [3] Group 2: Company Profile and Technology - Nameixin was established in 2021 and focuses on the research and development of mRNA vaccines and drugs, having built a comprehensive platform covering sequence design, delivery systems, and production processes [2] - The company has developed a leading technology system that includes AI-driven antigen design, proprietary mRNA optimization processes, and advanced lipid nanoparticle delivery methods [2] - Nameixin's first RSV mRNA freeze-dried vaccine received Phase I clinical approval by the end of 2024, marking a significant technological breakthrough and addressing global cold chain storage challenges [2] Group 3: Financial Projections - Revenue forecasts for the company are projected at 1.199 billion yuan, 1.36 billion yuan, and 1.478 billion yuan for 2025-2027, reflecting year-on-year changes of -16.23%, 13.40%, and 8.63% respectively [3] - Net profit attributable to the parent company is expected to be 212 million yuan, 327 million yuan, and 436 million yuan for the same period, with year-on-year growth rates of -46.84%, 54.49%, and 33.09% respectively [3]

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. plans to acquire 100% equity of Naimixin (Shanghai) Biotechnology Co., Ltd. through phased capital increase and equity transfer, aiming to integrate Naimixin's mRNA vaccine technology platform to accelerate its new generation vaccine R&D pipeline [1][2]. Group 1: Acquisition Details - The acquisition will proceed in three phases, starting with an investment of up to 120 million yuan for a 27.27% stake in Naimixin [1]. - Subsequent phases will depend on the clinical progress of Naimixin's core product, the RSV mRNA vaccine, and the development milestones of the HPV therapeutic vaccine project [1][2]. Group 2: Naimixin's Technology and Products - Naimixin has developed a comprehensive mRNA drug technology system covering sequence design, delivery systems, and production processes, with its core product being an RSV mRNA vaccine currently in Phase I clinical trials [2]. - The RSV vaccine utilizes a self-developed LNP delivery system and has shown over five times the neutralizing antibody levels compared to traditional inactivated vaccines in preclinical studies [2]. Group 3: Valuation and Milestones - The transaction employs a phased valuation linked to R&D progress, with pre-investment valuations set at a maximum of 320 million yuan, 440 million yuan, and 830 million yuan for each phase [3]. - The final transaction will be directly tied to clinical data from the RSV vaccine and results from the HPV therapeutic vaccine's dose escalation trials [3]. Group 4: Strategic Implications - This acquisition is the first significant merger since a state-owned investment group became the controlling shareholder of Kanghua Biological, potentially providing stronger financial and policy support for innovative drug development [3]. - The domestic market currently lacks a domestic RSV vaccine, and successful development of Naimixin's RSV mRNA vaccine could fill this market gap, marking a critical step in Kanghua Biological's strategic positioning in the biopharmaceutical frontier technology sector [3].

Core Viewpoint - The resignation of the president of Kanghua Biological, Wu Hongbo, is speculated to be linked to the company's significant decline in performance, with a projected net profit drop for 2025 compared to the previous year [2][3]. Company Performance - Kanghua Biological's latest performance forecast indicates a net profit attributable to shareholders for 2025 is expected to be between 191 million and 233 million yuan, a substantial decrease from 399 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be between 208 million and 230 million yuan, representing a year-on-year decline of 49.73% to 54.54% [2]. Reasons for Performance Decline - The decline in performance is attributed to two main factors: a decrease in vaccine sales revenue by approximately 11% due to industry policy adjustments and market competition, and the absence of overseas licensing income for the year 2025, which previously contributed significant profit [2][3]. - The company's product structure is overly reliant on a single product, the freeze-dried human rabies vaccine, which poses a risk as competition intensifies from other companies with similar products expected to be approved this year [3]. Control Change and Profit Guarantee - In July 2025, Kanghua Biological underwent a change in control, with the previous controlling shareholder transferring 21.91% of shares to Shanghai Wankexin Biological, resulting in a new controlling entity without an actual controller [3]. - A "profit guarantee agreement" was signed, stipulating that the company must achieve a total net profit of no less than 728 million yuan from 2025 to 2026, or compensate the acquirer for any shortfall [3][4]. Future Prospects - To address the dual challenges of performance guarantees and product singularity, Kanghua Biological is focusing on new product development, including the initiation of clinical trials for a new six-valent norovirus vaccine [4].

Group 1 - The core point of the article highlights the acceleration of domestic pharmaceutical mergers and acquisitions (M&A), with companies like Kanghua Biotech and China Biopharmaceutical leading the trend [1][5][8] - Kanghua Biotech announced its acquisition of Nameixin through capital increase and equity transfer, marking a significant move in the domestic M&A landscape [1] - The trend of M&A in China's innovative drug sector is seen as a response to the need for companies to enhance their capabilities and integrate resources [5][7] Group 2 - Historically, M&A activities in China's innovative drug sector have been limited due to various factors, including the ambition of biotech companies to grow independently and the insufficient quality of innovations [4][3] - The financial strength of domestic pharmaceutical companies is relatively lower compared to their international counterparts, with leading domestic firms holding around $20 billion in cash compared to over $300 billion for top global firms [4] - Recent M&A activities, although smaller in scale compared to international deals, indicate a shift towards realizing the value of existing capabilities within leading domestic companies [5][6] Group 3 - The M&A trend is driven by the need for domestic companies to leverage their clinical development and commercialization capabilities, as seen in the case of Kanghua Biotech and Nameixin [6][7] - The integration of resources through M&A is expected to enhance the competitive edge of domestic firms, allowing them to quickly fill technological gaps and expand their product pipelines [8][9] - The acceleration of internal circulation in the industry is anticipated to create a more favorable ecosystem for both large pharmaceutical companies and smaller biotech firms, fostering innovation and addressing unmet clinical needs [9][10]